Novo Holdings A/S’s Celldex Therapeutics CLDX Stock Holding History

Novo Holdings A/S’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38.1M	Sell	1,025,000 -175,000	-15%	-$5.65M	2.21%	17
2026 Q1	$38.1M	Hold	1,200,000	–	–	3.08%	13
2025 Q4	$32.6M	Hold	1,200,000	–	–	2.53%	17
2025 Q3	$31M	Hold	1,200,000	–	–	2%	17
2025 Q2	$24.4M	Hold	1,200,000	–	–	1.72%	18
2025 Q1	$21.8M	Buy	1,200,000 +200,000	+20%	+$4.47M	1.66%	18
2024 Q4	$25.3M	Buy	1,000,000 +36,337	+4%	+$987K	1.53%	18
2024 Q3	$32.8M	Buy	963,663 +113,663	+13%	+$4.33M	1.63%	18
2024 Q2	$31.5M	Buy	+850,000	New	+$32.1M	1.7%	18

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Novo Holdings A/S's CLDX Position: Q2 2026 in Review

Novo Holdings A/S reduced its Celldex Therapeutics (CLDX) stake by 15% in Q2 2026, selling an estimated $5.65M and leaving 1,025,000 shares worth $38.1M. The position accounts for 2.21% of the portfolio, ranked #17.

Novo Holdings A/S first reported a position in CLDX in Q2 2024 and has held it in 9 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Novo Holdings A/S held 1,025,000 shares of Celldex Therapeutics worth $38.1M as of Q2 2026.
Novo Holdings A/S sold 175,000 Celldex Therapeutics shares in Q2 2026, an estimated $5.65M.
Celldex Therapeutics made up 2.21% of Novo Holdings A/S's portfolio in Q2 2026, its #17 holding.
Novo Holdings A/S first reported a position in Celldex Therapeutics in Q2 2024 and has held it in 9 quarters since.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Novo Holdings A/S's 13F filing for Q2 2026, filed 14 Aug 2026.